Clinical Trial Update: Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rituximab biosimilar HLX01 plus CHOP versus rituximab with CHOP in previously untreated CD20+ diffuse large B-cell lymphoma has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• HLX01 (null)
• Rituximab (rituximab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: B-cell Non Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED